[HTML][HTML] Immunomodulatory effects and improved outcomes with cisplatin-versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer
MD Galsky, X Guan, D Rishipathak, AS Rapaport… - Cell Reports …, 2024 - cell.com
In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …
[HTML][HTML] Immunomodulatory effects and improved outcomes with cisplatin-versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer
MD Galsky, X Guan, D Rishipathak… - Cell Reports …, 2024 - ncbi.nlm.nih.gov
In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …
[HTML][HTML] Immunomodulatory effects and improved outcomes with cisplatin-versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer
MD Galsky, X Guan, D Rishipathak, AS Rapaport… - Cell Reports …, 2024 - Elsevier
In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …
Immunomodulatory effects and improved outcomes with cisplatin-versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer
M Galsky, X Guan, D Rishipathak, A Rapaport… - Cell reports …, 2024 - europepmc.org
In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …
Immunomodulatory effects and improved outcomes with cisplatin-versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer
MD Galsky, X Guan, D Rishipathak… - Cell reports …, 2024 - pubmed.ncbi.nlm.nih.gov
In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …
Immunomodulatory effects and improved outcomes with cisplatin-versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
MD Galsky, X Guan, D Rishipathak… - Cell reports …, 2024 - europepmc.org
In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …
control in a subset of patients. The IMvigor130 trial reveals more favorable effects with …